DMPA-SC Impact Model
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC), also known as Sayana Press, is an all-in-one injectable that can be administered by paraprofessionals or even clients themselves. Dozens of countries are exploring the benefits of adding this new easy-to-use contraception to the mix of currently available family planning methods. HP+ developed the DMPA-SC Impact Model to help project the benefits over five years that could come from the introduction of DMPA-SC, in terms of effects on contraceptive prevalence rate, increased access to family planning through public and private service delivery points, and costs to the health care system and clients.
Results from the model are primarily intended for advocacy or strategy development. Application of the model is envisioned as an in-country group activity in which a core model application group works with stakeholders to collect data, determine modelling scenarios, and validate results. The model was tested in Nigeria and further applied in Cameroon. In addition, two briefs are available with more information on the conceptual framework used to develop the model and applying a total market approach.
For assistance applying the model or to provide feedback on the model, contact: policyinfo@thepalladiumgroup.com.
